Literature DB >> 22030099

Association between PON1 activity and coronary heart disease risk: a meta-analysis based on 43 studies.

Yuan Zhao1, Yushui Ma, Ying Fang, Lili Liu, Shengdi Wu, Da Fu, Xiaofeng Wang.   

Abstract

Paraoxonase 1 (PON1) is reported to have antioxidant and cardioprotective properties. The relationship between PON1 activity and coronary heart disease (CHD) risk in humans has been reported among various ethnic populations in the past decade. However, these studies have yielded contradictory results. To investigate this inconsistency, we conducted a meta-analysis of 43 studies involving a total of 20,629 subjects to evaluate the effect of PON1 activity on susceptibility for CHD. We also systematically explored potential sources of heterogeneity using subgroup analysis and meta-regression. Significant decreases paraoxonase activity of PON1 were observed in CHD patients compared with non-CHD controls with SMD of -0.78 (95% CI: -0.98, -0.57; P<0.001). Similar results were also found for arylesterase activity of PON1 with SMD of -0.50 (95% CI: -0.64, -0.36; P<0.001). In the subgroup analysis by ethnicity, CHD phenotype, sample size, source of controls, mean age and BMI of cases, significantly increased risks were also found. In addition, our analyses detected a possibility of publication bias with an overestimate of the true association by smaller studies. This meta-analysis demonstrated that decreasing in PON1 activity is a risk factor associated with increased CHD susceptibility. However, additional very large-scale studies are warranted to provide conclusive evidence on the effects of PON1 activity on risk of CHD.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22030099     DOI: 10.1016/j.ymgme.2011.09.018

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  26 in total

Review 1.  Paraoxonases: metabolic role and pharmacological projection.

Authors:  Carlos Moya; Salvador Máñez
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-02-06       Impact factor: 3.000

2.  PON1 L55M and Q192R gene polymorphisms and CAD risks in patients with hyperlipidemia : Clinical study of possible associations.

Authors:  H Chen; S Ding; M Zhou; X Wu; X Liu; J Liu; Y Wu; D Liu
Journal:  Herz       Date:  2017-08-23       Impact factor: 1.443

Review 3.  Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis.

Authors:  Emanuele D'Amico; Pam Factor-Litvak; Regina M Santella; Hiroshi Mitsumoto
Journal:  Free Radic Biol Med       Date:  2013-06-21       Impact factor: 7.376

4.  Effect of Atorvastatin on Serum Para-Oxonase-1 and C-Reactive Protein in Wistar Rats.

Authors:  Aradhana Marathe; B Ganaraja; K Ashwin Shenoy; K Ashok Prabhu; M Nandini
Journal:  Indian J Clin Biochem       Date:  2018-03-17

5.  Organophosphate pesticides and PON1 L55M in Parkinson's disease progression.

Authors:  Kimberly C Paul; Janet S Sinsheimer; Myles Cockburn; Jeff M Bronstein; Yvette Bordelon; Beate Ritz
Journal:  Environ Int       Date:  2017-07-06       Impact factor: 9.621

Review 6.  Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity.

Authors:  Lucio G Costa; Gennaro Giordano; Toby B Cole; Judit Marsillach; Clement E Furlong
Journal:  Toxicology       Date:  2012-07-31       Impact factor: 4.221

7.  Identification of Critical Paraoxonase 1 Residues Involved in High Density Lipoprotein Interaction.

Authors:  Xiaodong Gu; Ying Huang; Bruce S Levison; Gary Gerstenecker; Anthony J DiDonato; Leah B Hazen; Joonsue Lee; Valentin Gogonea; Joseph A DiDonato; Stanley L Hazen
Journal:  J Biol Chem       Date:  2015-11-13       Impact factor: 5.157

Review 8.  Genetics of coronary artery disease and myocardial infarction.

Authors:  Xuming Dai; Szymon Wiernek; James P Evans; Marschall S Runge
Journal:  World J Cardiol       Date:  2016-01-26

9.  Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases.

Authors:  Dmitry Litvinov; Halleh Mahini; Mahdi Garelnabi
Journal:  N Am J Med Sci       Date:  2012-11

10.  Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine.

Authors:  Cüneyt Unsal; Yakup Albayrak; Neslihan Albayrak; Murat Kuloglu; Kenji Hashimoto
Journal:  Neuropsychiatr Dis Treat       Date:  2013-10-11       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.